Anti-HER2/neu therapy is well-established in breast and gastric carcinoma. The increased understanding of this pathway led to the identification of new promising drugs in addition to trastuzumab ...

Her2/neu immunostaining of formalin-fixed tumour tissues. Formalin-fixed, paraffin-embedded tissue blocks from the USC patients from whom primary cell lines were established were retrieved from ...

Your HER2 levels may change if your cancer comes back after treatment or spreads beyond the breast tissue. If this happens, your doctor may do a FISH test to understand which treatments will now ...

Their study, published in the online journal, Breast Cancer Research, on Nov. 29, 2004, showed that the vaccine protected 86 percent of experimental mice against HER2/neu-associated breast cancer ...

Based on successful animal studies, a novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some human breast cancers, say researchers at The ...

Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and more.

HER2/neu is a source of immunologic peptides and approximately 30% of early-stage breast cancers have an amplified HER2/neu gene or overexpression of its protein product. There has been a great ...

Again, the roughly 15% of cases that overexpress HER2/neu are referred to as HER2/neu-amplified or HER2/neu-positive; this is very relevant for the physician team taking care of the patient with ...

PATIENTS AND METHODS: Sixty-four patients with HER-2/neu–overexpressing breast, ovarian, or non–small-cell lung cancers were enrolled. Vaccines were composed of peptides derived from potential ...

TapImmune Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation into a Vaccine to Treat HER2/neu Breast Cancer Addition of Class I antigen provides new advance in development of ...

In late 2019, trastuzumab deruxtecan was approved for the treatment of metastatic HER2/neu-positive breast cancer based on a phase two single arm trial that showed an extremely high response rate ...